European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>Market assigns low odds to the current terms, with most of the expected value tied to deal failure or a materially higher exchange ratio.</li>
<li>BMPS now holds effective control, but the –3.5% spread shows investors doubt the deal will close as is without further sweetening.</li>
<li>No arbitrage setup is attractive, as convergence to the implied offer still implies a locked-in loss for Mediobanca holders at current market prices.</li>
</ul>


Market assigns low odds to the current terms, with most of the expected value tied to deal failure or a materially higher exchange ratio.
BMPS now holds effective control, but the –3.5% spread shows investors doubt the deal will close as is without further sweetening.
No arbitrage setup is attractive, as convergence to the implied offer still implies a locked-in loss for Mediobanca holders at current market prices.


BMPS–Mediobanca: Offer Live, Market Still Says No

<ul>
<li>CONSOB has approved the offer documentation, allowing the deal to proceed. The acceptance period runs from 14 July to 8 September, marking a key milestone in regulatory clearance.</li>
<li>Mediobanca trades at a premium to the implied offer price, indicating market skepticism and expectations of deal failure or an improved bid from BMPS to entice shareholder support.</li>
<li>The persistent negative spread—averaging −6% since January—reflects structural resistance, financial dilution, and shareholder opposition, undermining confidence in the transaction’s likelihood of completion.</li>
</ul>


CONSOB has approved the offer documentation, allowing the deal to proceed. The acceptance period runs from 14 July to 8 September, marking a key milestone in regulatory clearance.
Mediobanca trades at a premium to the implied offer price, indicating market skepticism and expectations of deal failure or an improved bid from BMPS to entice shareholder support.
The persistent negative spread—averaging −6% since January—reflects structural resistance, financial dilution, and shareholder opposition, undermining confidence in the transaction’s likelihood of completion.


<ul>
<li>Hostile Takeover Attempt: BMPS launched a €13.3B all-share bid for Mediobanca, offering a 5% premium, but Mediobanca rejected it, citing governance conflicts and strategic misalignment.</li>
<li>Shareholder and Dilution Risks: BMPS shareholders face 39.3% dilution, while Delfin and Caltagirone’s post-merger 24% stake raises governance concerns, potentially sidelining smaller investors.</li>
<li>The deal faces integration risks, and Mediobanca’s shareholder resistance, with BMPS’s falling stock price erasing the initial premium, making success increasingly uncertain.</li>
</ul>


Hostile Takeover Attempt: BMPS launched a €13.3B all-share bid for Mediobanca, offering a 5% premium, but Mediobanca rejected it, citing governance conflicts and strategic misalignment.
Shareholder and Dilution Risks: BMPS shareholders face 39.3% dilution, while Delfin and Caltagirone’s post-merger 24% stake raises governance concerns, potentially sidelining smaller investors.
The deal faces integration risks, and Mediobanca’s shareholder resistance, with BMPS’s falling stock price erasing the initial premium, making success increasingly uncertain.


BMPS's Hostile Takeover Bid for Mediobanca: Strategic and Financial Implications

<ul>
<li>Proposed Deal Details: BMPS launched a €13.3B all-share offer for Mediobanca, offering a 5% premium per share. Post-merger, BMPS shareholders would own 40% of the combined entity.</li>
<li>Strategic Rationale: The merger aims to create a diversified financial powerhouse, achieving €700M in annual synergies and accelerating BMPS’s €2.9B deferred tax asset utilization for shareholder value creation.</li>
<li>Challenges and Risks: Insufficient premium, integration complexities, and shareholder dilution concerns cast doubt on deal success, alongside Mediobanca’s superior growth prospects and market positioning.</li>
</ul>


Proposed Deal Details: BMPS launched a €13.3B all-share offer for Mediobanca, offering a 5% premium per share. Post-merger, BMPS shareholders would own 40% of the combined entity.
Strategic Rationale: The merger aims to create a diversified financial powerhouse, achieving €700M in annual synergies and accelerating BMPS’s €2.9B deferred tax asset utilization for shareholder value creation.
Challenges and Risks: Insufficient premium, integration complexities, and shareholder dilution concerns cast doubt on deal success, alongside Mediobanca’s superior growth prospects and market positioning.


Monte Dei Paschi Di Siena’s €13.3 Billion Bid for Mediobanca: First Take

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Hangzhou Kangji Medical Instrument Co., Ltd. / Event-Driven

Hangzhou Kangji Medical Instrument Co., Ltd.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/zeekr-intelligent-technology-holding" target="_blank" data-smartkarma-citation="entities:36785:1" rel="noopener">ZEEKR (ZK US)</a> traded wide to the scrip terms ahead of <a href="https://www.smartkarma.com/entities/geely-automobile-holdings-ltd" target="_blank" data-smartkarma-citation="entities:127:1" rel="noopener">Geely Auto (175 HK)</a>'s EGM Vote. That was a buying opportunity. </li>
<li>A positive surprise as SAMR expediently signs off on the <a href="https://www.smartkarma.com/entities/hangzhou-kangji-medical-instrument-co-ltd" target="_blank" data-smartkarma-citation="entities:28938:1" rel="noopener">Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK)</a> transaction. This could be wrapped up before Xmas.</li>
<li>
<a href="https://www.smartkarma.com/entities/china-mobile-ltd" target="_blank" data-smartkarma-citation="entities:27:1" rel="noopener">China Mobile (941 HK)</a> comfortably clears the 50% conditional threshold into <a href="https://www.smartkarma.com/entities/hkbn-ltd" target="_blank" data-smartkarma-citation="entities:289:1" rel="noopener">HKBN Ltd (1310 HK)</a>; however compulsory acquisition appears out of reach</li>
</ul>



ZEEKR (ZK US) traded wide to the scrip terms ahead of Geely Auto (175 HK)'s EGM Vote. That was a buying opportunity. 
A positive surprise as SAMR expediently signs off on the Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK) transaction. This could be wrapped up before Xmas.

China Mobile (941 HK) comfortably clears the 50% conditional threshold into HKBN Ltd (1310 HK); however compulsory acquisition appears out of reach


Last Week In Event SPACE: ZEEKR/Geely, Kangji Medical, HKBN, Lynas, Huaxin Cement, Nidec

Italy

Mediobanca S.p.A. is an investment bank in Italy, offering advisory services to domestic and international customers, and providing finance in its various forms from more traditional bank credit to the most sophisticated solutions available on capital markets. Banking activities on the retail side include consumer credit and mortgages offered alongside deposit gathering and wealth management.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mediobanca SpA (MB IM)

BMPS–Mediobanca: Offer Live, Market Still Says No

Mediobanca trades above BMPS’s implied offer, with a –3.5% spread. Market signals deal skepticism, favoring failure or a higher bid. Updated model...

Jesus Rodriguez Aguilar

BMPS-Mediobanca: Spread Says No

BMPS’s bid for Mediobanca trades at a persistent negative spread. Despite regulatory approval, market doubts remain high amid governance risks,...

Jesus Rodriguez Aguilar

BMPS's Hostile Takeover Bid for Mediobanca: Strategic and Financial Implications

BMPS's hostile takeover bid for Mediobanca faces governance conflicts, dilution risks, and shareholder resistance, with integration challenges and...

Jesus Rodriguez Aguilar

Monte Dei Paschi Di Siena’s €13.3 Billion Bid for Mediobanca: First Take

BMPS offers €13.3B all-share deal for Mediobanca, aiming to create financial powerhouse with €700M synergies but faces challenges with premium,...

Jesus Rodriguez Aguilar

Last Week In Event SPACE: ZEEKR/Geely, Kangji Medical, HKBN, Lynas, Huaxin Cement, Nidec

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BMPS–Mediobanca: Offer Live, Market Still Says No

Mediobanca trades above BMPS’s implied offer, with a –3.5% spread. Market signals deal skepticism, favoring failure or a higher bid. Updated model...

Jesus Rodriguez Aguilar

BMPS-Mediobanca: Spread Says No

BMPS’s bid for Mediobanca trades at a persistent negative spread. Despite regulatory approval, market doubts remain high amid governance risks,...

Jesus Rodriguez Aguilar

BMPS's Hostile Takeover Bid for Mediobanca: Strategic and Financial Implications

​BMPS's hostile takeover bid for Mediobanca faces governance conflicts, dilution risks, and shareholder resistance, with integration challenges and...

Jesus Rodriguez Aguilar

Monte Dei Paschi Di Siena’s €13.3 Billion Bid for Mediobanca: First Take

​BMPS offers €13.3B all-share deal for Mediobanca, aiming to create financial powerhouse with €700M synergies but faces challenges with premium,...

Jesus Rodriguez Aguilar

Last Week In Event SPACE: ZEEKR/Geely, Kangji Medical, HKBN, Lynas, Huaxin Cement, Nidec

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

BMPS's hostile takeover bid for Mediobanca faces governance conflicts, dilution risks, and shareholder resistance, with integration challenges and...

BMPS offers €13.3B all-share deal for Mediobanca, aiming to create financial powerhouse with €700M synergies but faces challenges with premium,...